MIS
Lambeth, United Kingdom
MIS
Lambeth, United Kingdom

Time filter

Source Type

Spinal Implants and Devices Market Progresses at a CAGR of 4.6%, Globally, by 2022 Spinal Implants and Devices Market Report, published by Allied Market Research, forecasts that the global market is expected to reach $13,384 million by 2022 from $9,741 million in 2015 with a CAGR of 4.6% from 2016 to 2022. Spinal fusion devices segment held nearly three-fifths of the total market share in 2015. Portland, OR, February 23, 2017 --( Advent of minimally invasive spine surgery techniques and rising incidence of spinal disorders drive the market growth. In addition, rise in geriatric population and technological developments in bone grafting products are anticipated to further drive the demand for spinal implants and devices globally. However, the unfavorable reimbursement scenario and stringent regulatory approval process are limitations that restrict the market growth. Spinal fusion implants are expected to dominate the market throughout the analysis period, owing to various advancements such as the advent of hook, rod and screw systems, which allow surgeons to correct spinal deformities in a three-dimensional way, and the development of special plates and cages that promote spinal fusion. Based on surgery, open spine surgery generated maximum revenue, accounting for almost two-third of the global spinal implants and devices market in 2015. However, the minimally invasive surgery market is estimated to exhibit the highest growth rate of 14.7% during the forecast period. Shift towards minimally invasive spine surgery (MIS) poses lucrative opportunities for key players in the spinal implants and devices market. MIS is preferred due to several benefits such as it does not involve a long cut or incision, which in turn reduces the chances of damage caused to the muscles surrounding the spine. Spinal Implants and Devices Market Key Findings: - In 2015, fusion implants led the overall spinal implants and devices market, and is projected to grow at a CAGR of 3.4% during the forecast period. - Non-fusion/motion preservation segment is projected to grow at a CAGR of 10.9% during the forecast period. - Dynamic stabilization devices segment is expected to grow at a significant CAGR of 10.9%, owing to the use of flexible materials during dynamic stabilization procedure that helps to retain mobility in the spine. - Balloon kyphoplasty occupied nearly four-fifth of the global vertebral compression fracture devices market in 2015. - Japan is the major shareholder, accounting for almost one-third of the Asia-Pacific spinal implants and devices market in 2015. Asia-Pacific is projected to grow at the highest CAGR of 5.7% during the forecast period owing to improvement in healthcare infrastructures and rise in expenditures in emerging markets (India and China) to overcome the unmet medical needs. Technological advancements to develop cost-effective devices in these nations offer a lucrative opportunity for market growth. The major companies profiled in the report include Alphatec Holdings, Inc., B. Braun Melsungen AG, Depuy Synthes (Johnson & Johnson), Exactech, Inc., Globus Medical, Inc., Medtronic plc, NuVasive, Inc., Orthofix International N.V., Stryker Corporation, and Zimmer Biomet Holdings, Inc. For more info visit: https://www.alliedmarketresearch.com/spinal-implants-and-spinal-devices-market Portland, OR, February 23, 2017 --( PR.com )-- Spine implants and devices are used to treat deformities and disorders related to the spine. The market has witnessed significant grown in the recent past due to the increase in government funding to support R&D for innovative spine treatment.Advent of minimally invasive spine surgery techniques and rising incidence of spinal disorders drive the market growth. In addition, rise in geriatric population and technological developments in bone grafting products are anticipated to further drive the demand for spinal implants and devices globally. However, the unfavorable reimbursement scenario and stringent regulatory approval process are limitations that restrict the market growth.Spinal fusion implants are expected to dominate the market throughout the analysis period, owing to various advancements such as the advent of hook, rod and screw systems, which allow surgeons to correct spinal deformities in a three-dimensional way, and the development of special plates and cages that promote spinal fusion.Based on surgery, open spine surgery generated maximum revenue, accounting for almost two-third of the global spinal implants and devices market in 2015. However, the minimally invasive surgery market is estimated to exhibit the highest growth rate of 14.7% during the forecast period.Shift towards minimally invasive spine surgery (MIS) poses lucrative opportunities for key players in the spinal implants and devices market. MIS is preferred due to several benefits such as it does not involve a long cut or incision, which in turn reduces the chances of damage caused to the muscles surrounding the spine.Spinal Implants and Devices Market Key Findings:- In 2015, fusion implants led the overall spinal implants and devices market, and is projected to grow at a CAGR of 3.4% during the forecast period.- Non-fusion/motion preservation segment is projected to grow at a CAGR of 10.9% during the forecast period.- Dynamic stabilization devices segment is expected to grow at a significant CAGR of 10.9%, owing to the use of flexible materials during dynamic stabilization procedure that helps to retain mobility in the spine.- Balloon kyphoplasty occupied nearly four-fifth of the global vertebral compression fracture devices market in 2015.- Japan is the major shareholder, accounting for almost one-third of the Asia-Pacific spinal implants and devices market in 2015.Asia-Pacific is projected to grow at the highest CAGR of 5.7% during the forecast period owing to improvement in healthcare infrastructures and rise in expenditures in emerging markets (India and China) to overcome the unmet medical needs. Technological advancements to develop cost-effective devices in these nations offer a lucrative opportunity for market growth.The major companies profiled in the report include Alphatec Holdings, Inc., B. Braun Melsungen AG, Depuy Synthes (Johnson & Johnson), Exactech, Inc., Globus Medical, Inc., Medtronic plc, NuVasive, Inc., Orthofix International N.V., Stryker Corporation, and Zimmer Biomet Holdings, Inc.For more info visit: https://www.alliedmarketresearch.com/spinal-implants-and-spinal-devices-market Click here to view the list of recent Press Releases from Allied Market Research


(PRLEAP.COM)– According to a new series of reports on the European dental implant fixture and final abutment market by iData Research ( www.idataresearch.com ), a growing prevalence of local manufacturers and increasingly cost-sensitive consumer demographic is contributing to overall price deprecation and the declining market share of premium implants. Historically, premium dental implant companies have dominated the competitive landscape in Europe but have recently faced rising competition from the value and discount brands."The increasing pricing pressure in the market has led premium implant companies to levy significant discounts on their products in order to remain competitive," explains Jeffery Wong, Strategic Analyst Manager at iData Research. "Regions with a larger presence of value and discount brands have been impacted most heavily and this limiting effect on overall growth is expected to continue over the next several years."However, despite persistent price depreciation, both mature and relatively underdeveloped markets continue to generate moderate levels of unit growth, thereby mitigating the net effect on market growth. For example, the key development within the final abutment market is the rapidly increasing uptake of patient-individualized CAD/CAM solutions and focus on digital dentistry. Additionally, a growing number of local laboratories have emerged to produce and distribute CAD/CAM abutments, making them more accessible. Market growth within these segments will be driven by increased penetration in relatively underdeveloped markets, such as France and the United Kingdom.Recent improvements in manufacturing capability and product affordability have resulted in rapid adoption of the CAD/CAM abutments, which offer significant progression in aesthetics and clinical outcomes, relative to the stock and custom cast abutments. It is expected that the European market will continue to adopt CAD/CAM technology, generating consistent growth for the final abutment market.Straumann is the leading competitor in the European dental implant fixture and final abutment market. Straumann's success can be attributed to its comprehensive product portfolio comprising traditional implants and abutments, as well as offerings that include ceramic implants, full arch restorations, CAD/CAM abutments and regenerative dental biomaterials. Furthermore, Straumann has continually reinforced its leading position in the market with strategic investments in value and discount implant companies such as Neodent, Biodenta, Medentika, MegaGen and Anthogyr. Continued expansion through strategic acquisitions and partnerships will aid Straumann in maintaining its leading position in the European dental implant market. Dentsply Sirona holds the second leading position in the market, benefitting from a strong presence across all market segments. Other leading competitors include Nobel Biocare, Zimmer Biomet, CAMLOG, Sweden & Martina, Medentis, MIS Implants and BEGO among others.More on the dental implant market in Europe can be found in a series of reports published by iData Research entitled the European Market Report Suite on Dental Implant Fixtures and Final Abutments . The suite covers reports on the following markets: dental implant fixtures, final abutments, treatment planning software and surgical guides.The iData report series on dental implants covers the U.S., Japan, South Korea, Australia, China,India, Brazil, Argentina, Mexico and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about dental implant market data or procedure data, register online or email us at info@idataresearch.net for a European Market Report Suite on Dental Implant Fixtures and Final Abutments brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Dental Prosthetics, Dental Lasers, Dental Materials, Dental Bone Graft Substitutes, Dental Implants, Dental CAD/CAM, Dental Operatory Equipment, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics and more.Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


News Article | March 1, 2017
Site: www.prweb.com

Sustainable Petroleum Group Inc. (the "Company") (OTCQB SPGX) is pleased to announce the appointment of additional officers and directors to further strengthen its management team and the implementation of its business strategy. Effective February 13, 2017, Christian Winzenried was appointed by the board of directors as the new President and CEO of SPGX. During the past five years, Mr. Winzenried has been an entrepreneur and executive officer in several companies in IT, Financial Services, Banking, Consulting and Lifestyle; most notably with zeb/ (a top management consultancy focusing on strategy, marketing, pricing and sales) where he was responsible for the development of business projects in the regional markets of Germany, Switzerland and Austria. For more than 20 years, Mr. Winzenried has taught Management and Leadership as well as SME Startup Founding processes at several Business Management Schools. He graduated with degrees in Leadership, Management of MIS/IT, Marketing and Economics. Also, on February 13, 2017 both Christian Winzenried and Stefan Mühlbauer were appointed as additional directors of SPGX. The board of directors of SPGX currently consists of Christian Winzenried (President and CEO), Suha Hächler (CFO, Treasurer, and Corporate Secretary), Stefan Mühlbauer (Chief Communications Officer), and Dr. Philip Grothe. Suha Hächler has been an entrepreneur and executive officer in several companies, including Xerox AG, where he was involved with the development and implementation of printing systems. Mr. Hächler is currently teaching business management consultancy at the international school Gustav Käser in Switzerland and also studied economics at the international school HSG St. Gallen in Switzerland. Dr. Philip Grothe has served as the CEO of alimex Group, a leading aluminum company, since 2014. Prior to joining alimex Dr. Grothe was partner and shareholder of Simon, Kucher & Partners, a top management consultancy focusing on strategy, marketing, pricing and sales. Dr. Grothe began his career at Deloitte Consulting where he worked as a manager and project leader in numerous marketing and sales projects. Dr. Grothe graduated with a degree in Economics and obtained his PhD in Strategic Management. Stefan Mühlbauer has served as CEO of Arma Communications Inc, a business development and marketing Agency in Naples, Florida since 2013. Additionally Mr. Mühlbauer serves as managing partner for Eagle Run Capital Inc. Previously, Mr. Mühlbauer held positions with various leading investment banks in Europe. Mr. Mühlbauer was the Chief Operating Officer at Silvia Quandt & Cie AG where he was responsible for building up the institution's research and corporate finance activities. Mr. Mühlbauer received his degree in Finance from the University of Miami. Christian Winzenried, the CEO of SPGX stated: "Together we are a very diverse management team with many years of expertise in leadership roles across a broad range of industries. As a team we look forward to developing continued shareholder value." About Sustainable Petroleum Group Inc. SPGX as a member of SP Group is positioned to become a world leading natural resources holding and development company through value based investments and collaborative partnerships with global leaders across the natural resources sector. SP Group has initiated its goals by pursuing investment and partnerships with some of the most diversified and integrated companies available on the market. On behalf of Sustainable Petroleum Group Inc. Christian Winzenried Chief Executive Officer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release contains statements that plan for or anticipate the future, called "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of those terms and other comparable terminology. These forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements about: our market opportunity; revenue generation; our strategies; competition; expected activities and expenditures as we pursue our business plan; the adequacy of our available cash resources; our ability to acquire assets or projects on commercially viable terms; challenges to our title to our assets; operating or technical difficulties in connection with our development activities; currency fluctuations; and governmental regulations. Many of these contingencies and uncertainties can affect our actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, us. Forward-looking statements are not guarantees of future performance. All of the forward-looking statements made in this press release are qualified by these cautionary statements. Specific reference is made to our most recent annual report on Form 10-KSB and other filings made by us with the United States Securities and Exchange Commission for more detailed discussions of the contingencies and uncertainties enumerated above and the factors underlying the forward-looking statements. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities and Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities and Exchange Commission at 1-800-SEC-0330. The U.S. Securities and Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities and Exchange Commission at http://www.sec.gov. We disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except to the extent required by applicable laws. This press release is for informational purposes only and is not and should not be construed as an offer to solicit, buy, or sell any security.


(PRLEAP.COM)– According to a new series of reports on the India market for vascular access devices and accessories by iData Research ( www.idataresearch.com ), the Indian government has been adamant on clearing regulatory hurdles related to imports and exports of medical devices, and has set new standards around clinical trials. In addition, the Indian government runs several health insurance programs designed for high-risk patients to pay upfront cash and then get reimbursed by filing a claim. However, this process has proven inefficient and major improvements are possible if better payment mechanisms are implemented. More reform is required to bring new opportunities to invest in the healthcare market and bring profound change to the healthcare landscape in India."The Indian market is still undergoing frequent changes in terms of regulations, shaped by efforts to contain the growing healthcare budget while supporting market growth and development," explains Jeffrey Wong, Strategic Analyst Manager of iData. "In addition to healthcare reforms, the government is encouraging private capital investment to improve service quality and meet the diverse and complex needs of the public."The largest and fastest growing vascular access device segment in India is the central venous catheter (CVC) market. Growth in this market has been driven by increasing hospitalizations and rising expenditures on healthcare. The growth rate in both conventional and antimicrobial CVC unit sales have been significant and are expected to continue as these devices are the primary vascular access devices used in India.The implantable ports market will also experience high growth due to product innovations such as power-injectable implantable ports, dual lumen ports and arm ports. Multi-lumen implantable ports are selling better than previously anticipated in India. Furthermore, the use of implantable ports in India is on the rise as soaring cancer rates continue to affect the country. According to the World Health Organization, over one million newly diagnosed cases of cancer were recorded in India in 2013. The resulting increased use of chemotherapy will require implantable ports.Teleflex leads the Indian vascular access device and accessories market due to their dominance in the CVC segment and notable presence in the peripherally inserted central catheter (PICC) segment. The acquisitions of companies such as VasoNova Inc. and Nostix LLC have positioned Teleflex as an emerging force in the tip guidance space and strengthened the company's global vascular access portfolio. Poly Medicure is the second largest competitor in India and the largest local competitor in the vascular access and accessories market. The company was able to establish an early presence in the Indian market for dialysis catheters, which translated to a substantial share in the overall market. Due to its low labor costs and brand recognition, the company was able to maintain its dominance in the dialysis catheter market. Additional competitors in the Indian vascular access device market include B. Braun, Becton Dickinson, C.R. Bard, Covidien and Smiths Medical among others.More on the vascular access device market in India can be found in a series of reports published by iData Research entitled the India Market Report Suite for Vascular Access Devices and Accessories . The suite covers reports on the following markets: implantable ports, port needles, central venous catheters (CVCs), peripherally inserted central catheters (PICCs), peripheral intravenous catheters (PIVCs), and dialysis catheters.The iData report series on vascular access devices covers the U.S., Japan, South Korea, Australia, China, India and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about vascular access device market data or procedure data, register online or email us at info@idataresearch.net for an India Market Report Suite for Vascular Access Devices and Accessories brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


(PRLEAP.COM)– iData Research ( www.idataresearch.com ) recently conducted a face-to-face survey for catheterization lab, structural heart and coronary stents during the 2016 Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, DC. Participants included cardiac surgeons, interventional cardiologists, interventional radiologists and general practitioners. Results have shown that clinical outcomes are the main deciding factor for respondents when choosing which brand of coronary stents to use. Respondents gave reasons for choosing a particular device, including price, availability of devices and existing relationships."This latest report is a global survey regarding demographic trends, concerns, experiences and preferences among cardiologists," explains Dr. Kamran Zamanian, CEO of iData. "Our iData team found answers to the questions posed by major cardiovascular device manufacturers regarding what they wanted to learn from the attendees of TCT 2016."Respondents came from a total of 57 countries. Each country has been subsequently categorized into six distinctive geographical regions: North America, Latin America, Europe, the Middle East, Africa and Asia. Within these regions, the United States, Brazil and Argentina represented the top three countries with the most respondents.The Global Survey on Catheterization Labs, Structural Heart and Coronary Stents by iData Research includes responses for the following questions*:*Results for each question are sorted globally and by regioniData's Global Physician Surveys are conducted by highly trained moderators with years of experience in applying iData's rigorous methodology to ensure balanced responses and to elicit keen insight from physicians, surgeons, specialists and other medical professionals. iData's Global Physician Surveys are used to garner brand awareness, product preferences, message feedback and positioning. iData's Physician Surveys allow the inclusion of a diverse range of medical professionals in broader geographical areas. They also eliminate group bias and allow for interactive one-on-one feedback as well as flexibility to expose the respondent to interactive or static media.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.


(PRLEAP.COM)According to a new series of reports on the Australia market for vascular access devices by iData Research ( www.idataresearch.com ), the use of peripherally inserted central catheters (PICCs) has grown significantly at the expense of central venous catheter (CVCs). The PIVC segment is growing rapidly as new technologies enter the market to focus on reducing infection rates and make PIVCs safer and easier to use. Nurse-led placement of PICCs has been a catalyst for the increasing adoption of PICCs which significantly lowers overall procedural cost. The combination of these factors will result in overall unit sales growth in the PICCs market.While the markets for traditional devices such as PICCs and CVCs are maturing, companies are actively investing in the development of new technological features that have increased average selling prices (ASPs) for these devices. New technologies are expected to have a significant impact on the vascular access device market. The competition in this market has spurred companies to differentiate their products in order to gain market share. This has consistently led to unique, premium-priced products."The more significant technological advancements will be in electrocardiogram (ECG) tip location," explains Dr. Kamran Zamanian, CEO of iData. "In addition, the increasing use of ultrasound has led to significant growth in the use of PICCs. Increasingly, ultrasound is being used for placement of PIVCs."Previously, implantable ports were thought to be a high potential market, owing to product innovations such as power-injectable implantable ports, dual lumen ports and arm ports. However, multi-lumen implantable ports have not sold as well as previously anticipated and the prices for power-injectable implantable ports have been decreasing dramatically. The price decreases of power-injectable implantable ports have been occurring as those devices become the standard of care in Australia and as manufacturers attempt to keep and gain market share by making their power-injectable devices more economically appealing.C. R. Bard is the leading competitor in the total Australian vascular access market. They are the strongest in the implantable port and PICC market, but also hold a significant share in the port needles market. The company has been extremely aggressive in their marketing and acquisition strategies in the vascular access market. In addition, the company continues to lead the way with new technologies, such as power-injectable devices. C. R. Bard takes advantage of the crossover between market segments and has been able to increase their presence in the rapidly growing complementary markets.Becton Dickinson is the second leading competitor, offering a wide variety of safety products. This company continues to innovate through the introduction of new products such as the Nexiva™ closed system PIVC. Additional competitors in this market include Teleflex Medical, B. Braun, Smiths Medical, Cook Medical, Medcomp, Angiodynamics, Medtronic and Baxter among others. B. Braun continues to invest in the PIVC market, with a particular focus on the safety PIVC segment.More on the vascular access device market in Australia can be found in a report suite published by iData Research entitled the Australia Market Report Suite for Vascular Access Devices and Accessories . The suite covers reports on the following markets: implantable ports, port needles, central venous catheters (CVCs), peripherally inserted central catheters (PICCs), peripheral intravenous catheters (PIVCs) and dialysis catheters.The iData report series on vascular access devices covers the U.S., Japan, South Korea, Australia, India, China, Brazil and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about vascular access device market data or procedure data, register online or email us at info@idataresearch.net for an Australia Market Report Suite for Vascular Access Devices and Accessories brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.


News Article | February 16, 2017
Site: globenewswire.com

FREMONT, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Electronics For Imaging™ (Nasdaq:EFII) announced today the launch of a new EFI Fiery® digital front end (DFE) that delivers the latest Fiery technology to increase performance and productivity on RICOH Pro 8200 Series black-and-white production printers. The new EFI Fiery EB-34 DFE is built on the latest Fiery FS200 Pro platform and delivers superior image quality in monochrome printing. Customers can take advantage of advanced job management and make-ready tools to streamline the print process with automated workflows. The new Fiery DFE also offers: “The RICOH Pro 8200 series empowers printers to produce a wide variety of applications very quickly and efficiently,” said John Fulena, Vice President, Production Printing Business Group, Ricoh USA, Inc. “The new EFI Fiery EB-34 DFE helps customers drive productivity, so they can minimize their prep time while maintaining close control over production management steps to help ensure exceptional results with this latest monochrome addition to our production print portfolio.” Ramp up your production with Fiery innovation “EFI continues to deploy its 20 years of developing industry-leading Fiery technology to the new RICOH Pro 8200 Series black-and-white print engines,” said John Henze, vice president, Fiery marketing, EFI. “Ricoh customers can achieve more without compromise using reliable EFI Fiery technology. With the new DFE offering, users gain a robust and unified digital print workflow that streamlines all aspects of their production – from job submission, job setup, make-ready, and automation to scheduling, invoicing and fulfillment.” Run a smooth operation with business-wide integration The Fiery EB-34 DFE also enables integration into existing production workflows for digital color and offset printing, giving print providers the ability to automate many business processes for greater flexibility with fewer touch points and reduced errors. Plus, the DFE can be included in end-to-end, certified workflows with EFI MIS/ERP and web-to-print products, including the EFI Midmarket Productivity Suite, the EFI Quick Print Suite and EFI Digital StoreFront® software for automated job submission and eCommerce, estimating, scheduling, job ticketing, accounting and other processes. The Fiery EB-34 DFE is available now from Ricoh and authorized Ricoh resellers. For more information about EFI Fiery Driven digital production printing, visit www.efi.com or contact 800-875-7117. About EFI EFI™ (www.efi.com) is a worldwide provider of products, technology and services leading the transformation of analog to digital imaging. Based in Silicon Valley, with offices around the globe, the company's powerful integrated product portfolio includes digital front-end servers; superwide, wide-format, label and ceramic inkjet presses and inks; production workflow, web to print, and business automation software; and office, enterprise and mobile cloud solutions. These products allow users to produce, communicate and share information in an easy and effective way, and enable businesses to increase their profits, productivity, and efficiency. Follow us on Twitter: https://twitter.com/EFIPrint Follow us on Instagram: https://www.instagram.com/efiprint Find us on Facebook: www.facebook.com/EFIPrint View us on YouTube: www.youtube.com/EFIDigitalPrintTech NOTE TO EDITORS:  The EFI logo, Fiery, Command WorkStation and Digital StoreFront are registered trademarks of Electronics For Imaging, Inc. in the U.S. and/or certain other countries. EFI, Fiery Driven, JobMaster and Navigator are trademarks of Electronics For Imaging, Inc. in the U.S. and/or certain other countries. All other terms and product names may be trademarks or registered trademarks of their respective owners, and are hereby acknowledged. Nothing herein should be construed as a warranty in addition to the express warranty statements provided with EFI products and services. This news release contains forward-looking statements, that are statements other than statements of historical fact including words such as “anticipate”, “believe”, “estimate”, “expect”, “consider”, “plan” and similar, any statements related to strategies or objectives of management for future operations, products, development, performance, any statements of assumptions or underlying any of the foregoing and any statements in the future tense.  Forward-looking statements are subject to certain risks and uncertainties that could cause our actual or future results to differ materially.  For further information regarding risks and uncertainties associated with EFI’s businesses, please refer to the risk factors section in the Company’s SEC filings, including, but not limited to, its annual report on Form 10-K and its quarterly reports on Form 10-Q. EFI undertakes no obligation to update information contained herein, including forward-looking statements.


News Article | February 16, 2017
Site: www.prweb.com

Vertebral Technologies, Inc. a MIS spinal implant medical device company based in Minneapolis, MN, has successfully moved their facilities from Minnetonka, MN to Minneapolis, MN. Brian Thron Director of Marketing says “the contemporary space compliments the company’s latest rebrand, with its simplistic design and modern color scheme. I’m pleased to call this space VTI’s new home”. “VTI’s new ISO Class 8 Controlled Environment is fully operational post the certification and validation testing process. In addition, the new facility allows VTI to take advantage of increased efficiency across multiple departments with a new office layout that encourages collaboration to everyday operations. We are looking forward to these operative advantages moving forward as VTI grows in 2017”. says Director of Manufacturing Brian Holmberg. President & CEO Matt Kyle stated "We are excited to be in our new space. The VTI team did a tremendous job of executing the move without disruption. The new space helps everyone align with our organizational objectives and growth focused culture. The feedback we have received, both internal and external, has been very positive." ABOUT VTI - VERTEBRAL TECHNOLOGIES, INC. VTI - Vertebral Technologies, Inc. is a privately held company based in Minneapolis, MN, USA. VTI is dedicated to the design, development, manufacturing and marketing of medical devices to address painful conditions of the spine through less-invasive surgical approaches. VTI’s products utilize its unique modular-assembly technology to deliver solutions optimized for both surgeons and their patients. VTI sells its InterFuse® modular interbody fusion devices worldwide. For more information, visit: http://www.vti-spine.com or contact Brian Thron at marketing(at)vti-spine(dot)com or + 1.877.912.5401.


News Article | February 22, 2017
Site: www.nature.com

According to a recent review19, an objective criterion for an interglacial is the absence of substantial Northern Hemisphere ice outside Greenland. This criterion is supported by the observation45 that when the ice-volume component of a benthic oxygen isotope record was separated from the deep-water-temperature component, it reached close to the modern value in all the prominent isotopic highstands of the past 1.5 Myr. Assuming that there is little difference in Antarctic ice volume between interglacials, this criterion equates to a sea-level definition. Looking at only the past 800 kyr, it was proposed19 that an interglacial occurred if sea level reached above –20 m compared to the present-day level. It was also suggested that, to be considered a separate interglacial, sea level must pass below a second valley threshold on either side of the peak19. This definition suggests a roster of 11 interglacials since 800 kyr bp (Fig. 1)19. However, differences between sea-level reconstructions left ambiguity. To obtain a more robust result, sensitivity studies were carried out using the LR04 benthic isotope stack20. This has the disadvantage that it contains a component of deep-water temperature as well as ice volume, but the advantage that it is based on many datasets and is therefore robust against the appearance of new data. Using LR04, it was found that a wide range of thresholds (δ18O between 3.5‰ and 3.73‰) led to the same roster of interglacials19. This confirms that, for the past 800 kyr, there is a clear gap between the population of interglacials and the population of interstadials. No threshold was specified for the depth of the ‘valley’ that would distinguish two separate interglacials from a continuing one. However, MIS 15b was considered to to separate two interglacials, whereas MIS 7b was not; this puts limits on the acceptable valley depth. In the earlier part of the Quaternary, there are not sufficiently precise sea-level data to attempt to choose an interglacial roster on the basis of sea level, so we are forced to use benthic isotope records. The main benthic record we use is the LR04 stack20, which consists of 57 datasets, although the number is substantially fewer in the first part of the Quaternary compared to the past 800 kyr. The resolution of the LR04 record changes for increasing age: it is 1 kyr for 0–600 kyr bp, 2 kyr for 600–1,500 kyr bp, and 2.5 kyr before that. To ensure that our interglacial definitions are comparable along the record, we used a smoothed version (to 2-kyr resolution) of LR04 between 0 kyr bp and 600 kyr bp. This has the effect of ensuring that very short (1 kyr) excursions cannot be interpreted as interglacials. Before 800 kyr bp in LR04 there is no longer a range of values that clearly separates the interglacial and interstadial population, forcing us to choose a set threshold. An estimate of sea level45 clearly suggests that most isotopic lows between MIS 21 and 49 should be defined as interglacials. This requires that the threshold between interglacials and interstadials needs to be towards the high end of the 3.50‰–3.73‰ range used previously. At 3.73‰ we are uncomfortably close to making MIS 5c (minimum 3.75‰) an interglacial, despite strong evidence19 that it was an interstadial. At 3.71‰ we would exclude MIS 27, and at 3.66‰ MIS 33. There is then a gap until beyond 3.58‰ (at which MIS 41 would be excluded, followed closely by others). We must therefore choose where we place the threshold between 3.73‰ and 3.58‰, and our choice determines the assignment of MIS 27 and 33. LR04 has the drawback that in periods in which the underlying data are poorly resolved or the age matching between records is uncertain, the amplitude of peaks could be reduced. Therefore, in addition to the averaged LR04 curve, we also looked at two marine sequences covering this period. One dataset is the composite record (referred to as S05) of Eastern Equatorial Pacific sites: V19–30 (0–341 kyr bp)51, V19–28 (341–430 kyr bp)52, V19–25 (430–460 kyr bp) (N. J. Shackleton, unpublished data), ODP 677 (460–1,809 kyr bp)24 and ODP 846 (1,812–2,600 kyr bp)53. The other dataset is a new well-resolved record U1308 (ref. 32) from the North Atlantic. Although MIS 27 is a very weak peak in both these records, MIS 33 is very clear, especially in U1308, in which it is stronger than several peaks that we have classed as interglacial. For this reason, we chose to set the threshold at 3.68‰, thus defining MIS 33 as interglacial and MIS 27 as interstadial. This choice of threshold allows us to apply an objective and consistent method to derive our taxonomy; other choices could have been made, leading to a different population of interglacials. For ages less than 1.5 Myr bp, establishing the valley depth needed to define separate interglacials was relatively straightforward. The distinction is important because the climate dynamics involved in the transition from a glacial to an interglacial are different from those involved in maintaining an existing ice-free status. On the basis of the past 800 kyr, this valley threshold could fall anywhere between 3.82‰ and 4.32‰ without changing the roster of interglacials (either dividing MIS 7a and 7c or combining MIS 15a with 15c–e). The lower amplitude of cycles in the earlier part of the Pleistocene requires a low threshold for valley depth to avoid classifying long sequences of data as interglacial, so we adopt a value of 3.92‰ (only 0.24‰ above the interglacial threshold). Before 1.5 Myr bp, there is a clear trend in isotopic values in LR04 and other benthic isotope records over the earlier part of the record. Because this applies also to the ‘peaks’ (lowest δ18O values), yet Northern Hemisphere ice volume cannot be negative, it suggests that the trend is due to other factors: an increase in deep-water temperatures or a decrease in Antarctic ice volume. We therefore detrend LR04 linearly before 1.5 Myr bp (Extended Data Fig. 1a, b)—an age chosen because it appears that deep-water temperature in interglacials did not increase between 1.5 Myr bp and 1 Myr bp (ref. 45). The detrended values are calculated as where A is the age (kyr bp). We maintain the same thresholds (3.68‰ and 3.92‰) for the detrended record. For each insolation maximum, we seek an obvious minimum in LR04 that falls either just before, or within 10 kyr after, the insolation maximum. The reason for allowing this wide range is twofold: (i) we expect a lag of ice volume behind the insolation forcing by a few thousand years, but the tuning of LR04 to an insolation target is sufficiently imprecise that occasionally it will slightly lead the insolation, and may lag by as much as 10 kyr; (ii) if there is no noticeable peak within this range then we assess the value of the LR04 data at the insolation maximum itself. This will apply only in the case of some continued interglacials, for which we have to decide whether the system is still in an interglacial state at the insolation maximum that follows the one that caused deglaciation. In the earlier part of the record (>1.5 Myr bp), this method leads to serveral borderline cases. To assess these we again referred to the two discrete records, S05 and U1308. We use the S05 composite record by detrending it linearly before 1.5 Myr bp, as in the case of the LR04 record (Extended Data Fig. 1c, d). The detrended values for S05 are calculated as We set the thresholds 3.88‰ and 4.12‰ for the detrended S05 record, maintaining the difference of 0.24‰ as in LR04. We used U1308 qualitatively to assess the status of any peak that is borderline in LR04. In assigning interglacial status we give LR04 primacy, because it consists of several marine records, carefully combined (Supplementary Table 1). For borderline cases in LR04 (within 0.04‰ of the interglacial threshold) we applied the following criteria: if both S05 and U1308 agree with LR04 (or if one agrees and the other is also borderline), then the assignment is confirmed; if one agrees and one clearly disagrees, then we retain the LR04 assignment but treat it as uncertain (open symbol in our figures); or, if both disagree with LR04, then we overturn the assignment but treat it as uncertain. Supplementary Table 1 shows all the uncertain assignments and our reasoning, with those δ18O peaks especially discussed shown enlarged in Extended Data Figs 2 and 3. We discuss some examples below. For MIS 61 (insolation peak at 1,739 kyr bp), LR04 only marginally exceeds the threshold as an interglacial (Extended Data Fig. 2). The value is below the threshold in S05 (Extended Data Fig. 3), but the peak in U1308 is reasonably strong, so the peak is classed as interglacial but uncertain (Supplementary Table 1). In LR04, MIS 67 is a continuation of MIS 69 rather than a separate interglacial—even a tiny change in the separation threshold of 3.92‰ would have overturned this classification. In this case, U1308 agrees with no separation, whereas there is clear separation in S05, which questions this assignment. We assigned MIS 67 as a continued interglacial but uncertain (Supplementary Table 1). MIS 71 would not be classed as interglacial in LR04; it is not especially weak in either S05 or U1308, and for that reason we classed it as an uncertain interglacial even though it just fails the test in LR04 (Supplementary Table 1). We recommend caution for any conclusions that rely on these assignments. One interglacial, MIS 59, requires a special discussion. In all of LR04, S05 and U1308 there is a clear interglacial peak after the insolation peak at 1,697 kyr bp, but well before the next one at 1,663 kyr bp. However, our threshold is first passed only 11 kyr (LR04) and 14 kyr (S05) after the insolation peak, outside the criterion we set (Extended Data Figs 2 and 3). Nonetheless, given that there is no other possible match of insolation peak to a LR04/S05 minimum, we assume that this large lag results either from the fact that the insolation peak is wide, with a shoulder near the databased interglacial maximum, or from a tuning issue in the age models. We therefore classed the insolation peak at 1,697 kyr bp as being associated with an interglacial (Supplementary Table 1). Finally, we note that the only interval of above-average obliquity before 1 Myr bp that is not associated with an interglacial or a continued interglacial is the one containing the insolation peak at 2,062 kyr bp, which is classified as a definite interstadial. However, despite the clear assignment in LR04 (which is given primacy in our classification scheme), 2,062 kyr bp is classified as a clear interglacial in S05. Because the position of the diagonal line separating interglacials from interstadials and continued interglacials in Extended Data Fig. 5b (and of the horizontal line on the right-hand side of Fig. 5) is constrained by the insolation peak at 2,062 kyr bp, this is one part of the record for which further data are required. The outcome of all of this discussion is that every insolation maximum is classed as associated with an interglacial, a continued interglacial or an interstadial (although in some cases no obvious interstadial peak is visible). In a small number of cases, these assignments are classed as uncertain. Our classification is firm according to the rules we have set, but other rules would change some of the assignments, particularly those classed as uncertain. The insolation data shown in the figures and Supplementary Tables 1 and 2 are based on the algorithm for computing astronomical parameters50, available in the software package palinsol54, developed for R. The solar constant used is 1,368 W m−2. with P the probability of an interglacial onset, I the peak summer caloric insolation and Δt the time since the onset of the previous interglacial. Although the model is calibrated under this form using Jeffrey’s priors for β , β and β (ref. 55), it can be rewritten as with σ = 1/β , E  = −β σ and b = β σ, where b is the discount rate and E is the deglaciation threshold. The parameter σ is a measure of stochasticity. In the limit σ → ∞, all events occur with a probability of 50%. In the limit σ → 0, all events occur with a probability of 1 or 0, depending on whether the effective energy exceeds the deglaciation threshold E or not. The system is then deterministic. Jeffrey’s prior puts more weight on large values of σ, which means that deglaciation events are a priori stochastic. The likelihood associated with one observation is then P if this observation is an interglacial onset, and 1 − P otherwise. If the observation is treated as uncertain (see text)—we assign a 10% probability of misattribution whether or not the observation is an interglacial onset—then the likelihood is 0.9P + 0.1(1 − P) for an interglacial onset, and 0.1P + 0.9(1 − P) otherwise. One recommendation55 is to seek the posterior maximum, and then estimate the posterior distribution by importance sampling to improve on the Laplacian approximation. We found this procedure problematic, especially with the ramp model (see below), because several local maxima may exist. We instead estimated the maximum posterior and used the Hessian matrix to build a proposal for a Metropolis Hastings posterior sampling. We ran 40 Metropolis Hastings Markov chains. Each chain was skimmed to suppress sample auto-correlations, and the 40 chains were combined with weights equal to their respective marginal likelihoods (estimated using truncated harmonic means, following ref. 56). The resulting parameter distributions were then sampled to estimate plausible histories over the past 1 Myr. We generalize the model as follows for application over the past 2.6 Myr. The deglaciation threshold E changes linearly between two dates denoted A and A , with the difference in threshold between ages A and A equal to ΔE (see Fig. 5). The model is then A and A are parameterized as follows: We adopt uniform priors for ΔE, A and ΔA. We find the discount rate b to be the same (within uncertainties) regardless of whether the model is calibrated only over the past 1 Myr (Fig. 4) or over the past 2.6 Myr with the ramp function (Extended Data Fig. 5). The posterior distribution of A and A are shown in Extended Data Fig. 10. In the main text we discussed a model for the occurrence of interglacial onsets based on the caloric summer half-year insolation1 at 65° N, calculated from the orbital solution of ref. 50. Extended Data Figs 6, 7, 8, 9 show the model results obtained by using the summer solstice mean daily insolation at 65° N (ref. 50) instead. Whereas the caloric summer half-year insolation at 65° N has almost equal contributions from precession and obliquity, the summer solstice mean daily insolation at 65° N has 80% of its variance in the precession band. The summer solstice insolation curve at 65° N over the past 2.6 Myr is presented as the black curve in Extended Data Fig. 6. The red, black and light blue symbols indicate the summer solstice insolation maxima nearest to the interglacial onsets, continued interglacials and interstadials, respectively. They are classified by the same criteria explained in Methods section ‘Definition of interglacials’. Results are listed in Supplementary Table 2. In about 90% of cases, summer solstice insolation maxima occur near (±5 kyr) caloric summer insolation maxima, but the former has additional peaks due to the stronger precession component; for example, a single peak at 51 kyr bp in the caloric summer insolation at 65° N is split into two peaks at 38 kyr bp and 58 kyr bp in the summer solstice insolation at 65° N. Peak summer solstice insolation for interglacials, continued interglacials and interstadials is plotted as a function of age in Extended Data Fig. 7. Unlike caloric summer insolation (Fig. 3), it is difficult to draw a simple summer solstice insolation threshold that separates interglacials from interstadials before 1 Myr bp. According to our model, an interglacial onset occurs when a peak insolation exceeds a threshold line that decreases with time since the previous deglaciation (the slope of the line is referred to as the ‘discount rate’ of the insolation required for deglaciation). Extended Data Fig. 8 shows the peak summer solstice insolation at 65° N as a function of the time since the onset of the previous interglacial during the time intervals 0–1 Myr bp (Extended Data Fig. 8a), 1–1.5 Myr bp (Extended Data Fig. 8b, inset) and 1.5–2.6 Myr bp (Extended Data Fig. 8b). Whereas in the past 1 Myr it is possible to define an optimum threshold line (dashed line in Extended Data Fig. 8a) with one of false negative (MIS 11c) and one false positive (979 kyr bp), any straight threshold line before 1.5 Myr bp produces several false positives or a combination of false positives and false negatives. The effective energy at each summer solstice insolation peak is calculated according to equation (1), but with a discount rate of 0.575 W m−2 kyr−1, estimated from Extended Data Fig. 8a. A complete deglaciation occurs when this effective energy exceeds the deglaciation threshold E (indicated by the y intercept of the diagonal line in Extended Data Fig. 8a). Extended Data Fig. 9 shows the effective energy at each insolation peak as a function of age, underlining the absence of a simple threshold in effective energy before 1 Myr bp. These results suggest that summer solstice insolation at 65° N is a weaker predictor of interglacials than the caloric summer half-year insolation at 65° N. The benthic isotope records and insolation data analysed in this study and the code to reproduce the experiments are available from https://github.com/mcrucifix/logistic_insol


News Article | February 23, 2017
Site: globenewswire.com

CARLSBAD, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will release fourth quarter and full year 2016 financial results after the close of trading on Thursday, March 2, 2017.  The Company’s management team will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET to discuss the financial results and recent business developments. Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 58687870. The webcast will also be available on the SeaSpine website following the completion of the call. To listen to the webcast, please visit the investor relations section of the SeaSpine website at www.seaspine.com. SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures.  SeaSpine's spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.

Loading MIS collaborators
Loading MIS collaborators